about
Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphomaPhase I/II Study of Pralatrexate in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma.E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase 1 study.Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trialPossibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotinMultiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatmentBone marrow involvement by monomorphic epitheliotropic intestinal T-cell lymphoma
P50
Q33443153-265BDD73-0F3D-40CE-B1BF-804C62347B36Q33738783-F6D844E7-8C59-4CCD-A494-DDBDF5373812Q38644090-C47CC8B9-3818-4343-A087-0D9F9EED83C3Q49834009-987D3395-C962-411A-9CF5-B8F99A3F20A6Q52686509-D8406919-8F38-4E48-AF66-B1EECA4765EFQ58762364-5F586D2B-C0E2-4102-AC39-49A25DAA0EFEQ64108842-A8E4A376-19FB-4E49-8DBD-DA65EF035032Q92359322-1263C22A-3B7A-4BF0-B09D-D19EB5B82074Q93032719-8F81A7E2-0093-4EBB-8CB1-85B9EC95C30AQ93034303-4D2B277E-4D5D-4E54-ACCF-F1C64B79E969
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Dai Maruyama
@en
Dai Maruyama
@nl
type
label
Dai Maruyama
@en
Dai Maruyama
@nl
prefLabel
Dai Maruyama
@en
Dai Maruyama
@nl
P31
P496
0000-0003-0654-6920